EAU NMIBC Risk Calculator - Calculator

EAU NMIBC Risk Group Calculator

If the patient has primary carcinoma in situ (CIS) (no concomitant papillary tumors), the patient is included in the High-Risk Group.

If the patient has either CIS in the prostatic urethra, lympho-vascular invasion, or one of the following variant histologies: micropapillary, plasmacytoid, sarcomatoid, or neuroendocrine, the patient is included in the Very High-Risk Group. There are insufficient data to classify the other variant histologies as being either High Risk or Very High Risk.

To calculate the risk group for other patients, enter their characteristics. Enter either the World Health Organization (WHO) 1973, the WHO 2004/2016, or both grading classification systems.

You must agree with the terms to use the calculator.

Age

≤ 70 years
> 70 years

Tumor Status

Primary
Recurrent

Number of Tumors

Single
Multiple

Maximum Tumor Diameter

< 3 cm
≥ 3 cm

Stage

Ta
T1

Concomitant CIS

No
Yes

Select Classification System

Either the WHO 1973, the WHO 2004/2016, or both grading classification systems can be selected.

WHO Grade 2004/2016

LMP-LG
HG

WHO Grade 1973

G1
G2
G3
The form is incomplete, please review it to unlock the "Calculate" button bellow.

Results

Probability of progression after TURBT without induction or maintenance BCG
Based on WHO 2004/2016 Based on WHO 1973
at 1 year
at 5 years
at 10 years
Probability of Progression and 95% Confidence Interval
Share result
You have selected HG and G1
Are you sure you want to use both?
You have selected LMP-LG and G3
Are you sure you want to use both?

Clinical composition of the new EAU NMIBC prognostic factor risk groups based on WHO 2004/2016 or WHO 1973 grading classification systems

Low Risk

A primary, single, Ta LG/G1 tumor ≤ 3 cm in diameter without CIS in a patient ≤ 70 years


A primary LG/G1 tumor with at most ONE of the following additional clinical risk factors:

Intermediate Risk

Patients without CIS who are not included in either the low, high or very high-risk groups

High Risk

All T1 HG/G3 without CIS, EXCEPT those included in the very high-risk group

All CIS patients, EXCEPT those included in the very high-risk group


Stage, grade with additional clinical risk factors*:

Very High Risk

Stage, grade with additional clinical risk factors*:


Tumors with:

* The additional clinical risk factors are age > 70, multiple tumors, and tumor diameter ≥ 3 cm

Risk Groups Table

Risk Group Probability of Progression and 95% Confidence Interval
1 Year 5 Years 10 Years
New Risk Groups with WHO 2004/2016
Low 0.06%, 0.01%-0.43% 0.93%, 0.49%-1.7% 3.7%, 2.3%-5.9%
Inter 1.0%, 0.50%-2.0% 4.9%, 3.4%-7.0% 8.5%, 5.6%-13%
High 3.5%, 2.4%-5.2% 9.6%, 7.4%-12% 14%, 11%-18%
Very High 16%, 10%-26% 40%, 29%-54% 53%, 36%-73%
New Risk Groups with WHO 1973
Low 0.12%, 0.02%-0.82% 0.57%, 0.21%-1.5% 3.0%, 1.5%-6.3%
Inter 0.65%, 0.36%-1.2% 3.6%, 2.7%-4.9% 7.4%, 5.5%-10%
High 3.8%, 2.6%-5.7% 11%, 8.1%-14% 14%, 10%-19%
Very High 20%, 12%-32% 44%, 30%-61% 59%, 39%-79%

About

This app estimates the probability of a Non–muscle Invasive Bladder Cancer (NMIBC) patient’s progression to MIBC after trans-urethral resection of bladder tumours (TURBT) and calculates their updated European Association of Urology (EAU) Prognostic Factor Risk Group. It Incorporates both the WHO 2004/2016 and WHO 1973 Grading Classification Systems and is based on the following publication:

Sylvester RJ, et al. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. Eur Urol (2021), https://doi.org/10.1016/j.eururo.2020.12.033

It is a tool that can be used to help inform treatment decisions, but it does not provide professional advice and it can never replace clinical expertise. Treatment decisions for individual patients should take into account not only clinical expertise, but also patient personal values and their preferences.

This calculator has been developed by Ydeal for the EAU. Its developers and its distributors assume no responsibility for the accuracy of the results that are provided or for possible flaws in the system. Nor are they liable for special, direct, indirect or consequential damages, charges, claims, costs, demands, losses, fees or expenses of any nature or kind arising from use of the system.

Comments, suggestions and any errors that are found should be sent to info@nmibc.net

© European Association of Urology

By using the system, the User agrees to these conditions and to abide by international copyright laws and all other applicable laws involving copyright.

Translations